CHO Genome Hotspots for Stable, High-Yield Biopharmaceutical Production
By targeting specific genomic loci associated with high expression, this approach significantly reduces the time and cost involved in developing high-performing and stable CHO clones.
Technology
Chinese hamster ovary (CHO) cell lines are the most commonly used platform for manufacturing biopharmaceuticals, primarily due to their ability to produce recombinant products suitable for human disease treatment and intervention. CHO cells are favored not only for their efficient processing of therapeutic proteins but also for their well-established regulatory pathways recognized by health authorities worldwide. Despite their widespread use, the traditional methods of utilizing CHO cells for bioproduction are inefficient. Current manufacturing processes rely on random integration followed by selection pressure to identify CHO clones that express high levels of recombinant proteins, which are crucial for reducing production costs. This random integration strategy is time-consuming and costly, as it requires extensive efforts to identify clones that are both high-performing and stable. To overcome the inefficiencies associated with traditional CHO cell line development, research is increasingly focusing on site-specific integration approaches. This method allows for the targeted integration of therapeutic transgenes into specific genomic loci within CHO cells. By selecting loci known for high levels of product expression, companies can significantly accelerate the development of high-performing CHO clones. The inventors at UD have employed genome-wide scanning techniques to identify novel hotspots within the CHO genome that are suitable for stable integration and associated with high expression. These identified genomic loci have demonstrated significant industrial application potential, as they are capable of supporting elevated levels of biopharmaceutical production. The adoption of site-specific integration technology in CHO cell line development offers a transformative value proposition for biopharmaceutical manufacturers. By targeting specific genomic loci associated with high expression, this approach significantly reduces the time and cost involved in developing high-performing and stable CHO clones. This technology positions companies to maintain a competitive edge in the rapidly evolving biopharmaceutical industry by streamlining the development process and optimizing resource allocation.
Benefits
- Reduced Development Time: Site-specific integration accelerates the identification and development of high-performing CHO clones, shortening the overall timeline for bringing biopharmaceuticals to market.
- Cost Efficiency: By targeting genomic loci associated with high expression, the technology reduces the costs associated with traditional random integration methods.
- High Protein Titers: Ensures consistent and elevated levels of recombinant protein production.
- Suitable for testing in any CHO host.
Applications
- Production of therapeutic proteins, including monoclonal and bispecific antibodies.
- Suitable for biomanufacturing and bioprocessing companies.